COMPANY

IGC Pharma

HQ: Potomac, MD source · igcpharma.com ↗ · Mid-Atlantic

Keywords: neurology Alzheimer Disease Agitation,Psychomotor Care Giving Burden Aggression Dementia of Alzheimer Type IGC-AD1-Active IGC AD1

Location: Potomac, MD · source · Aug 14, 2026

Profile checked Oct 10, 2026

Timeline

Mar 30, 2026 Partnership Partnership / licensing announced Mar 30, 2026. Source: SEC filing. source ↗
Sep 9, 2025 Grant Government grant announced Sep 9, 2025. Source: company's own press page. source ↗
Oct 11, 2022 Trial start Phase 2: Clinical Trial on Agitation in Alzheimer's Dementia source ↗
Jan 11, 2021 Trial start Phase 1: Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease source ↗

2026-11 (ESTIMATED) · Phase 2 · Clinical Trial on Agitation in Alzheimer's Dementia · NCT05543681

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Mar 30, 2026 Partnership / licensing announced Mar 30, 2026. Source: SEC filing. source ↗
Sep 9, 2025 Government grant announced Sep 9, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05543681	Clinical Trial on Agitation in Alzheimer's Dementia	Phase 2	Active, not recruiting	Oct 11, 2022	2026-11 (estimated)
NCT04749563	Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease	Phase 1	Completed	Jan 11, 2021	Jun 20, 2021 (actual)